TVTX · Travere Therapeutics, Inc.
$56.49
+0.58 (+1.04%)
At close · Jul 29
Market Cap
$5.20B
Shares
92.99M
Travere Therapeutics, Inc. Earnings Call Transcripts
Every quarterly earnings call for Travere Therapeutics, Inc. (TVTX) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▼21.6%
$53.50M
−$69.66M
'22 Q3
22-10-27
▼48.8%
$29.34M
−$65.82M
'22 Q4
23-01-09
▲17.5%
$56.99M
−$86.33M
'23 Q1
23-05-04
▲10.2%
$59.70M
−$85.63M
'23 Q2
23-08-03
▼30.7%
$37.09M
$150.74M
'23 Q3
23-11-07
▲53.6%
$45.06M
−$90.17M
'23 Q4
24-02-15
▼27.4%
$41.37M
−$136.06M
'24 Q1
24-05-06
▼9.3%
$54.12M
−$70.41M
'24 Q2
24-08-01
▲69.6%
$62.90M
−$54.81M
'24 Q3
24-10-31
▲66%
$74.79M
−$60.26M
'24 Q4
25-02-20
▲97.5%
$81.73M
−$41.23M
'25 Q1
25-05-01
▲111.5%
$114.45M
−$12.76M
'25 Q2
25-08-06
▲162.1%
$164.86M
$25.71M
'25 Q3
25-10-30
▲73.4%
$129.69M
$2.73M
'25 Q4
26-02-19
LATEST
▲55.6%
$127.20M
−$37.10M
'26 Q1
26-05-04
Earnings call
FY26 · Q2
2026-08-04
Travere Therapeutics Second Quarter 2026 Earnings Results
Scheduled
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-06-08
Goldman Sachs 47th Annual Global Healthcare Conference 2026
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-06-03
2026 Jefferies Global Healthcare Conference
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-05-13
BofA Securities 2026 Health Care Conference
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-05-04
Travere Therapeutics, Inc. Q1 FY2026 Earnings Call
Confident tone
FSGS approval and launch
IgA nephropathy commercial performance
FSGS patient eligibility and sequencing
Revenue
$127.20M
▲ 55.6% YoY Diluted EPS
$-0.40
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-02-19
Travere Therapeutics, Inc. Q4 FY2025 Earnings Call
Confident tone
FILSPARI commercial performance in IgA nephropathy
Cross-indication synergy between IgAN and FSGS
FSGS regulatory path and PDUFA
Revenue
$129.69M*
▲ 73.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Conference
Investor event
2026-01-12
44th Annual J.P. Morgan Healthcare Conference
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY25 · Q3
2025-10-30
Travere Therapeutics, Inc. Q3 FY2025 Earnings Call
Confident tone
FILSPARI commercial growth in IgA nephropathy
FSGS approval opportunity and launch readiness
REMS modification and potential full removal
Revenue
$164.86M
▲ 162.1% YoY Diluted EPS
$0.28
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-06
Travere Therapeutics, Inc. Q2 FY2025 Earnings Call
Confident tone
FILSPARI IgAN commercial performance
FSGS sNDA and regulatory progress
Clinical evidence and SPARTAN/PROTECT data
Revenue
$114.45M
▲ 111.5% YoY Diluted EPS
$-0.14
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-01
Travere Therapeutics, Inc. Q1 FY2025 Earnings Call
Confident tone
FILSPARI in IgA Nephropathy
KDIGO Guidelines and Treatment Practice Changes
FILSPARI sNDA for FSGS
Revenue
$81.73M
▲ 97.5% YoY Diluted EPS
$-0.47
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-02-20
Travere Therapeutics, Inc. Q4 FY2024 Earnings Call
Confident tone
FILSPARI commercial momentum in IgAN
Pre-commercial readiness for potential FSGS launch
FSGS expansion opportunity
Revenue
$74.79M*
▲ 66% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-10-31
Travere Therapeutics, Inc. Q3 FY2024 Earnings Call
Confident tone
REMS liver monitoring modification
FILSPARI IgAN launch
KDIGO guidelines / treatment threshold
Revenue
$62.90M
▲ 69.6% YoY Diluted EPS
$-0.70
▼ 135.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-01
Travere Therapeutics, Inc. Q2 FY2024 Earnings Call
Confident tone
FILSPARI launch performance and demand growth
sNDA review and anticipated full approval
FSGS and PARASOL regulatory path
Revenue
$54.12M
▼ 9.3% YoY Diluted EPS
$-0.91
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-06
Travere Therapeutics, Inc. Q1 FY2024 Earnings Call
Confident tone
FILSPARI U.S. commercial launch
IgAN treatment paradigm shift
Pegtibatinase / HARMONY Phase 3 program
Revenue
$41.37M
▼ 27.4% YoY Diluted EPS
$-1.76
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-15
Travere Therapeutics, Inc. Q4 FY2023 Earnings Call
Confident tone
FILSPARI launch momentum in IgAN
Long-term kidney function data (PROTECT 2-year)
sNDA submission for full approval
Revenue
$45.06M
▲ 53.6% YoY Diluted EPS
$-1.18
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-07
Travere Therapeutics, Inc. Q3 FY2023 Earnings Call
Revenue
$37.09M
▼ 30.7% YoY Diluted EPS
$1.97
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-03
Travere Therapeutics, Inc. Q2 FY2023 Earnings Call
Revenue
$59.70M
▲ 10.2% YoY Diluted EPS
$-1.13
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-04
Travere Therapeutics, Inc. Q1 FY2023 Earnings Call
Revenue
$56.99M
▲ 17.5% YoY Diluted EPS
$-1.27
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-01-09
Travere Therapeutics, Inc. Q4 FY2022 Earnings Call
Revenue
$29.34M
▼ 48.8% YoY Diluted EPS
$-1.03
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-10-27
Travere Therapeutics, Inc. Q3 FY2022 Earnings Call
Revenue
$53.50M
▼ 21.6% YoY Diluted EPS
$-1.09
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-04
Travere Therapeutics, Inc. Q2 FY2022 Earnings Call
Revenue
$54.17M
▼ 0.8% YoY Diluted EPS
$-1.05
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-05
Travere Therapeutics, Inc. Q1 FY2022 Earnings Call
Revenue
$48.49M
▲ 2.3% YoY Diluted EPS
$-1.20
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-01-10
Travere Therapeutics, Inc. Q4 FY2021 Earnings Call
Revenue
$57.25M*
▲ 12.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-10-28
Travere Therapeutics, Inc. Q3 FY2021 Earnings Call
Revenue
$68.22M
▲ 33.4% YoY Diluted EPS
$-0.59
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-07-29
Travere Therapeutics, Inc. Q2 FY2021 Earnings Call
Revenue
$54.62M
▲ 12.8% YoY Diluted EPS
$-0.64
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-06
Travere Therapeutics, Inc. Q1 FY2021 Earnings Call
Revenue
$47.41M
▼ 0.8% YoY Diluted EPS
$-0.96
▼ 4900% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-02-10
Travere Therapeutics, Inc. Q4 FY2020 Earnings Call
Revenue
$50.98M
▲ 9.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-05
Travere Therapeutics, Inc. Q3 FY2020 Earnings Call
Revenue
$51.14M
▲ 15.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-07-30
Travere Therapeutics, Inc. Q2 FY2020 Earnings Call
Revenue
$48.43M
▲ 8.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-05-11
Travere Therapeutics, Inc. Q1 FY2020 Earnings Call
Revenue
$47.77M
▲ 20.7% YoY Diluted EPS
$0.02
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Showing 1–30 of 30 earnings calls
Key facts
CIK
1438533
CUSIP
89422G107
13F (30d)
41 filings
41 filers
Visit website
Investor relations